COVID-19 Transformation to Help Global qPCR and dPCR Instrumentation Market Reach USD 9.2 Billion by 2026
|
By LabMedica International staff writers Posted on 04 Jun 2021 |

Illustration
The global market for quantitative PCR (qPCR) and digital PCR (dPCR) instrumentation estimated at USD 5.2 billion in 2020 is projected to grow at a CAGR of 9.8% to reach USD 9.2 billion by 2026, driven by opportunities and challenges in a significantly transformed post COVID-19 marketplace.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
Channels
Clinical Chemistry
view channel
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
Pseudomonas aeruginosa is a major cause of hospital-acquired and ventilator-associated pneumonia, particularly in lung transplant recipients and patients with structural lung disease. Its ability to form... Read moreMolecular Diagnostics
view channel
World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device
Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more
Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae
Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read moreBlood Test Could Detect Adverse Immunotherapy Effects
Immune checkpoint inhibitors have transformed cancer treatment, but they can also trigger serious immune-related adverse events that damage healthy organs and may become life-threatening if not detected early.... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read morePathology
view channel
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read moreTechnology
view channel
Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. Treatment is particularly challenging because the tumor infiltrates... Read more
Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more






 Analyzer.jpg)

